FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155199102> ?p ?o ?g. }

• W3155199102 endingPage "1394" @default.
• W3155199102 startingPage "1383" @default.
• W3155199102 abstract "BackgroundGiven the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential paediatric use. We aimed to assess the safety and immunogenicity of an MF59-adjuvanted subunit vaccine for COVID-19 based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a novel molecular clamp (spike glycoprotein-clamp [sclamp]).MethodsWe did a phase 1, double-blind, placebo-controlled, block-randomised trial of the sclamp subunit vaccine in a single clinical trial site in Brisbane, QLD, Australia. Healthy adults (aged ≥18 to ≤55 years) who had tested negative for SARS-CoV-2, reported no close contact with anyone with active or previous SARS-CoV-2 infection, and tested negative for pre-existing SARS-CoV-2 immunity were included. Participants were randomly assigned to one of five treatment groups and received two doses via intramuscular injection 28 days apart of either placebo, sclamp vaccine at 5 μg, 15 μg, or 45 μg, or one dose of sclamp vaccine at 45 μg followed by placebo. Participants and study personnel, except the dose administration personnel, were masked to treatment. The primary safety endpoints included solicited local and systemic adverse events in the 7 days after each dose and unsolicited adverse events up to 12 months after dosing. Here, data are reported up until day 57. Primary immunogenicity endpoints were antigen-specific IgG ELISA and SARS-CoV-2 microneutralisation assays assessed at 28 days after each dose. The study is ongoing and registered with ClinicalTrials.gov, NCT04495933.FindingsBetween June 23, 2020, and Aug 17, 2020, of 314 healthy volunteers screened, 120 were randomly assigned (n=24 per group), and 114 (95%) completed the study up to day 57 (mean age 32·5 years [SD 10·4], 65 [54%] male, 55 [46%] female). Severe solicited reactions were infrequent and occurred at similar rates in participants receiving placebo (two [8%] of 24) and the SARS-CoV-2 sclamp vaccine at any dose (three [3%] of 96). Both solicited reactions and unsolicited adverse events occurred at a similar frequency in participants receiving placebo and the SARS-CoV-2 sclamp vaccine. Solicited reactions occurred in 19 (79%) of 24 participants receiving placebo and 86 (90%) of 96 receiving the SARS-CoV-2 sclamp vaccine at any dose. Unsolicited adverse events occurred in seven (29%) of 24 participants receiving placebo and 35 (36%) of 96 participants receiving the SARS-CoV-2 sclamp vaccine at any dose. Vaccination with SARS-CoV-2 sclamp elicited a similar antigen-specific response irrespective of dose: 4 weeks after the initial dose (day 29) with 5 μg dose (geometric mean titre [GMT] 6400, 95% CI 3683–11 122), with 15 μg dose (7492, 4959–11 319), and the two 45 μg dose cohorts (8770, 5526–13 920 in the two-dose 45 μg cohort; 8793, 5570–13 881 in the single-dose 45 μg cohort); 4 weeks after the second dose (day 57) with two 5 μg doses (102 400, 64 857–161 676), with two 15 μg doses (74 725, 51 300–108 847), with two 45 μg doses (79 586, 55 430–114 268), only a single 45 μg dose (4795, 2858–8043). At day 57, 67 (99%) of 68 participants who received two doses of sclamp vaccine at any concentration produced a neutralising immune response, compared with six (25%) of 24 who received a single 45 μg dose and none of 22 who received placebo. Participants receiving two doses of sclamp vaccine elicited similar neutralisation titres, irrespective of dose: two 5 μg doses (GMT 228, 95% CI 146–356), two 15 μg doses (230, 170–312), and two 45 μg doses (239, 187–307).InterpretationThis first-in-human trial shows that a subunit vaccine comprising mammalian cell culture-derived, MF59-adjuvanted, molecular clamp-stabilised recombinant spike protein elicits strong immune responses with a promising safety profile. However, the glycoprotein 41 peptide present in the clamp created HIV diagnostic assay interference, a possible barrier to widespread use highlighting the criticality of potential non-spike directed immunogenicity during vaccine development. Studies are ongoing with alternative molecular clamp trimerisation domains to ameliorate this response.FundingCoalition for Epidemic Preparedness Innovations, National Health and Medical Research Council, Queensland Government, and further philanthropic sources listed in the acknowledgments." @default.
• W3155199102 created "2021-04-26" @default.
• W3155199102 creator A5004904922 @default.
• W3155199102 creator A5014301435 @default.
• W3155199102 creator A5019747461 @default.
• W3155199102 creator A5022968105 @default.
• W3155199102 creator A5029246358 @default.
• W3155199102 creator A5033648075 @default.
• W3155199102 creator A5035218973 @default.
• W3155199102 creator A5039006639 @default.
• W3155199102 creator A5041196894 @default.
• W3155199102 creator A5045601532 @default.
• W3155199102 creator A5047348044 @default.
• W3155199102 creator A5048221378 @default.
• W3155199102 creator A5049119347 @default.
• W3155199102 creator A5049459345 @default.
• W3155199102 creator A5050060053 @default.
• W3155199102 creator A5052065093 @default.
• W3155199102 creator A5056103685 @default.
• W3155199102 creator A5058215158 @default.
• W3155199102 creator A5058862688 @default.
• W3155199102 creator A5059750741 @default.
• W3155199102 creator A5061874732 @default.
• W3155199102 creator A5064780677 @default.
• W3155199102 creator A5069128652 @default.
• W3155199102 creator A5069450540 @default.
• W3155199102 creator A5070784934 @default.
• W3155199102 creator A5071536993 @default.
• W3155199102 creator A5072101136 @default.
• W3155199102 creator A5072766818 @default.
• W3155199102 creator A5074756673 @default.
• W3155199102 creator A5076277347 @default.
• W3155199102 creator A5076840670 @default.
• W3155199102 creator A5077015392 @default.
• W3155199102 creator A5080907867 @default.
• W3155199102 creator A5083922647 @default.
• W3155199102 creator A5090943299 @default.
• W3155199102 date "2021-10-01" @default.
• W3155199102 modified "2023-10-17" @default.
• W3155199102 title "Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial" @default.
• W3155199102 cites W1507692039 @default.
• W3155199102 cites W1968763470 @default.
• W3155199102 cites W2017219476 @default.
• W3155199102 cites W2048092342 @default.
• W3155199102 cites W2073228170 @default.
• W3155199102 cites W2076213364 @default.
• W3155199102 cites W2085743609 @default.
• W3155199102 cites W2095633747 @default.
• W3155199102 cites W2129973151 @default.
• W3155199102 cites W2171157147 @default.
• W3155199102 cites W2175677032 @default.
• W3155199102 cites W2199119140 @default.
• W3155199102 cites W2399997331 @default.
• W3155199102 cites W2411091524 @default.
• W3155199102 cites W2418848084 @default.
• W3155199102 cites W2738554310 @default.
• W3155199102 cites W2787000680 @default.
• W3155199102 cites W2901328586 @default.
• W3155199102 cites W2932795656 @default.
• W3155199102 cites W3009335299 @default.
• W3155199102 cites W3011224398 @default.
• W3155199102 cites W3013374708 @default.
• W3155199102 cites W3027204812 @default.
• W3155199102 cites W3041502662 @default.
• W3155199102 cites W3042833857 @default.
• W3155199102 cites W3043722389 @default.
• W3155199102 cites W3044482768 @default.
• W3155199102 cites W3044722686 @default.
• W3155199102 cites W3045724532 @default.
• W3155199102 cites W3045870925 @default.
• W3155199102 cites W3046061621 @default.
• W3155199102 cites W3047896956 @default.
• W3155199102 cites W3048620154 @default.
• W3155199102 cites W3081892744 @default.
• W3155199102 cites W3112131943 @default.
• W3155199102 cites W3112218407 @default.
• W3155199102 cites W3119345685 @default.
• W3155199102 cites W3129083220 @default.
• W3155199102 cites W3146889037 @default.
• W3155199102 cites W4206708282 @default.
• W3155199102 doi "https://doi.org/10.1016/s1473-3099(21)00200-0" @default.
• W3155199102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8055208" @default.
• W3155199102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33887208" @default.
• W3155199102 hasPublicationYear "2021" @default.
• W3155199102 type Work @default.
• W3155199102 sameAs 3155199102 @default.
• W3155199102 citedByCount "70" @default.
• W3155199102 countsByYear W31551991022021 @default.
• W3155199102 countsByYear W31551991022022 @default.
• W3155199102 countsByYear W31551991022023 @default.
• W3155199102 crossrefType "journal-article" @default.
• W3155199102 hasAuthorship W3155199102A5004904922 @default.
• W3155199102 hasAuthorship W3155199102A5014301435 @default.
• W3155199102 hasAuthorship W3155199102A5019747461 @default.
• W3155199102 hasAuthorship W3155199102A5022968105 @default.
• W3155199102 hasAuthorship W3155199102A5029246358 @default.
• W3155199102 hasAuthorship W3155199102A5033648075 @default.
• W3155199102 hasAuthorship W3155199102A5035218973 @default.

• next